首页> 美国卫生研究院文献>World Journal of Gastroenterology >Metabolic and hepatic effects of liraglutide obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis

【2h】

Metabolic and hepatic effects of liraglutide obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis

机译：利拉鲁肽奥贝胆酸和弹性纤维蛋白在饮食诱发的活检证实的非酒精性脂肪性肝炎的肥胖小鼠模型中的代谢和肝效应

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

AIMTo evaluate the pharmacodynamics of compounds in clinical development for nonalcoholic steatohepatitis (NASH) in obese mouse models of biopsy-confirmed NASH.

机译：目的在活检证实的NASH肥胖小鼠模型中评估非酒精性脂肪性肝炎（NASH）临床开发中化合物的药效学。

著录项

期刊名称 World Journal of Gastroenterology
作者
Kirstine S Tølbøl; Maria NB Kristiansen; Henrik H Hansen; Sanne S Veidal; Kristoffer TG Rigbolt; Matthew P Gillum; Jacob Jelsing; Niels Vrang; Michael Feigh;
展开▼
作者单位

展开▼
年(卷),期 2018(24),2
年度 2018
页码 179–194
总页数 17
原文格式 PDF
正文语种
中图分类肠道病毒与肝炎病毒 ; 肝及胆疾病 ; 肠疾病 ;
关键词
Nonalcoholic steatohepatitis Disease models Pathology Fibrosis Liver biopsy Transcriptomics Pharmacodynamics Glucagon-like peptide-1 receptor Peroxisome proliferator-activated receptor Farnesoid X receptor;

机译：非酒精性脂肪性肝炎;疾病模型;病理学;纤维化;肝活检;转录组学;药效学;胰高血糖素样肽1受体;过氧化物酶体增殖物激活受体;法呢素X受体;

相似文献

外文文献
中文文献
专利

1. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis [J] . Kirstine S T?lb?l, Maria NB Kristiansen, Henrik H Hansen, World Journal of Gastroenterology . 2018 ,第2期

机译：利拉鲁肽，奥贝胆酸和弹性纤维蛋白在饮食诱发的活检证实的非酒精性脂肪性肝炎的肥胖小鼠模型中的代谢和肝效应
2. Metabolic and hepatic effects of clinical candidates liraglutide, elafibranor and obeticholic acid in obese mouse models with diet-induced and biopsy-confirmed NASH [J] . Feigh Michael, Veidal Sanne Skovgaard, Tolbol Kirstine S., Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2017 ,第Suppla1期

机译：患有饮食诱导和活检证实的肿瘤患者在肥胖小鼠模型中临床候选人，Elafibranor和Obeticholic酸的代谢和肝酸的肝癌
3. Global characterization of gene expression regulation by clinical candidates liraglutide, elafibranor and obeticholic acid in a diet-induced obese mouse model with biopsy-confirmed NASH [J] . Rigbolt Kristoffer, Tolbol Kirstine S., Feigh Michael, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2017 ,第Suppla1期

机译：临床候选肝脏，Elafibranor和饮食诱导的肥胖小鼠模型中患者患者的基因表达调控的全局表征，具有活组织检查证实的纳什
4. Lipidomics of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in a Mouse Model via LC-HRMS [C] . Rainey E. Patterson, Srilaxmi Kalavalapalli, Nishanth E. Sunny, ASMS Conference on Mass Spectrometry and Allied Topics . 2015

机译：通过LC-HRMS在小鼠模型中非酒精性脂肪肝疾病和非酒精脂肪肝炎的脂质组
5. Effects of adipogenesis on insulin sensitivity: Two time-course studies in diet-induced obese mouse models [D] . Loe, Yu-chi Cynthia 2008

机译：脂肪形成对胰岛素敏感性的影响：饮食诱导的肥胖小鼠模型中的两个时程研究
6. Both Elafibranor and Liraglutide Improve NAFLD / NASH but Affect Differentially the Hepatic Lipidome and Metabolome in a Diet-Induced Obese and Biopsy-Confirmed Mouse Model of NASH [O] . Nikolaos Perakakis, Konstantinos Stefanakis, Michael Feigh, 2021

机译：Elafibranor和Liraglutide都改善了Nafld / Nash但在饮食诱导的肥胖和活检证实的纳什小鼠模型中影响差异肝脏脂质体和代谢物
7. Both Elafibranor and Liraglutide Improve NAFLD / NASH but Affect Differentially the Hepatic Lipidome and Metabolome in a Diet-Induced Obese and Biopsy-Confirmed Mouse Model of NASH [O] . Nikolaos Perakakis, Konstantinos Stefanakis, Michael Feigh, 2021

机译：Elafibranor和Liraglutide都改善了Nafld / Nash，但在饮食诱导的肥胖和活检证实的纳什小鼠模型中影响差异肝脏脂质体和代谢物

Metabolic and hepatic effects of liraglutide obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis

摘要

著录项

相似文献

相关主题

期刊订阅